quinazolines has been researched along with epz-6438 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brainson, CF; Byrd, AL; Chen, F; DuCote, TJ; Liu, J; Song, X; Wang, C | 1 |
| Adib, D; Gupta, D; Mamlouk, K; Nellesen, D; Proudman, D; Yang, J | 1 |
1 review(s) available for quinazolines and epz-6438
| Article | Year |
|---|---|
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-
Topics: Benzamides; Biphenyl Compounds; Child, Preschool; Heterocyclic Compounds, 4 or More Rings; Humans; Isoquinolines; Lymphoma, Follicular; Morpholines; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Purines; Pyridones; Pyrimidines; Quinazolines; Quinazolinones; Risk | 2022 |
1 other study(ies) available for quinazolines and epz-6438
| Article | Year |
|---|---|
EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.
Topics: Animals; Antineoplastic Agents; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Humans; Lung Neoplasms; Mice; Morpholines; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2022 |